Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 5.192
Filtrar
1.
Urol Clin North Am ; 49(2): 197-207, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35428426

RESUMO

Urologists may commonly diagnose hypogonadism in adult men experiencing an age-related decline in serum testosterone. Low serum testosterone in conjunction with symptoms such as decreased libido, fatigue, memory deficit, or decreased vitality is described as testosterone deficiency syndrome. There are numerous therapeutic options, although each is unique in its formulation, administration, and side-effect profile. For this reason, treatment can prove to be challenging for each unique patient case. The clinician must carefully monitor key serum markers before and during treatment. With careful dosing and monitoring, therapeutic benefit can be achieved reliably and sustainably.


Assuntos
Hipogonadismo , Testosterona , Adulto , Humanos , Hipogonadismo/diagnóstico , Hipogonadismo/tratamento farmacológico , Libido , Masculino , Síndrome , Testosterona/uso terapêutico
2.
Urol Clin North Am ; 49(2): 299-307, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35428435

RESUMO

Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal women. Menopause hormone therapy (systemic and local) is the mainstay for individualized management of women at midlife.


Assuntos
Disfunções Sexuais Fisiológicas , Disfunções Sexuais Psicogênicas , Feminino , Humanos , Libido , Pré-Menopausa , Comportamento Sexual/psicologia , Disfunções Sexuais Fisiológicas/diagnóstico , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Disfunções Sexuais Psicogênicas/diagnóstico , Disfunções Sexuais Psicogênicas/tratamento farmacológico
3.
Age Ageing ; 51(4)2022 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-35429269

RESUMO

BACKGROUND: erectile dysfunction is associated with mortality, whereas the association between low testosterone (T) and higher mortality remains controversial. Sexual dysfunction and low T often coexist, but the relative importance of sexual symptoms versus low T in predicting mortality is not known. We studied the interrelationships between sex steroids and sexual symptoms with all-cause mortality in a large prospective cohort of European men. DESIGN: survival status was assessed in 1,788 community-dwelling men, aged 40-79, who participated in the European Male Ageing Study (EMAS). Sexual symptoms were evaluated via a validated questionnaire (EMAS-SFQ). Sex steroids were measured by mass spectrometry. Cox proportional hazard models were used to study the association between hormones, sexual symptoms and mortality. RESULTS: about 420 (25.3%) men died during a mean follow-up of 12.6 ± 3.1 years. Total T levels were similar in both groups, but free T was lower in those who died. Men with three sexual symptoms (erectile dysfunction, reduced morning erections and lower libido) had a higher mortality risk compared with men with none of these symptoms (adjusted hazard ratio (HR) and 95% confidence intervals: 1.75 (1.28-2.40, P = 0.001)). Particularly, erectile dysfunction and poor morning erections, but not lower libido, were associated with increased mortality (HR 1.40 (1.13-1.74, P = 0.002), 1.28 (1.04-1.59, P = 0.023) and 1.12 (0.90-1.39, P = 0.312), respectively). Further adjusting for total T, free T or oestradiol did not influence the observed risk. CONCLUSIONS: sexual symptoms, in particular erectile dysfunction, predict all-cause mortality independently of sex steroids and can be an early warning sign of a poor health status.


Assuntos
Disfunção Erétil , Idoso , Envelhecimento , Disfunção Erétil/diagnóstico , Feminino , Humanos , Libido , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Testosterona
4.
Artigo em Inglês | MEDLINE | ID: mdl-35410031

RESUMO

Recent literature has extensively examined sexual behavior during lockdown due to COVID-19. However, there are no recent studies that have considered the relationship between body image quality, sexual arousability, and sexual anxiety. The present study has two main objectives: (1) to examine gender differences in bodily and sexual experience; and (2) the comparison of bodily and sexual experience, before and during the COVID-19 lockdown. A total of 301 adult subjects (161 women and 140 men) aged between 16 and 73 years (Mean = 37.4; S.D. = 10.3) participated in the study. Data on biographical information were collected via an online panel. The Body Uneasiness Test (BUT) and the Sexual Arousability Inventory (SAI) were used for the assessment. Univariate ANOVA showed worse scores for women, compared with men, in terms of body image avoidance, depersonalization, overall severity of body image quality, sexual arousability, and sexual anxiety dimensions. When compared against time, only women showed significant correlations between the function of sexual arousal and all parameters concerning body image alteration. Interestingly, these correlations were weak and sporadic before lockdown, but strong and numerous during lockdown. This finding suggests that the impact of COVID-19 restrictions affected the female population more, with a profound repercussion on self-image and sexual and mental well-being.


Assuntos
Imagem Corporal , COVID-19 , Adolescente , Adulto , Idoso , COVID-19/epidemiologia , Controle de Doenças Transmissíveis , Feminino , Humanos , Libido , Masculino , Pessoa de Meia-Idade , Fatores Sexuais , Adulto Jovem
5.
Biomed Pharmacother ; 148: 112765, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35247715

RESUMO

Oxidative stress has been linked with sleep deprivation (SD)-induced pathological conditions and reproductive dysfunction. On the other hand, glutamine has been established to have antioxidant property. However, the impact of SD, with or without glutamine, on male reproductive function is yet to be elucidated. Thus, this study was designed to investigate the role of SD, with or without glutamine, on male reproductive function and possible associated mechanisms. Ten-week old male Wistar rats weighing 175.6 g± 0.42 were randomly assigned into vehicle that received per os (p.o.) distilled water, glutamine (1 g/kg; po), SD, and SD + glutamine that received treatments as glutamine and SD. Treatment/exposure lasted for 72 h. The results showed that SD led to reduced body weight, seminiferous luminal and epididymal sperm density, low sperm quality, increased testicular and epididymal malondialdehyde, uric acid, DNA fragmentation, and testicular injury markers. In addition, SD caused a reduction in reduced glutathione level and activities of superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, glutathione peroxidase, and glutathione-S-transferase. Also, SD increased tumor necrotic factor-α, interleukin-1ß, and nuclear factor-kappa B levels. Furthermore SD led to impaired libido and erectile dysfunction, and suppression of circulatory nitric oxide, gonadotropins and testosterone, and penile cGMP. However, glutamine attenuated the effects induced by SD. Taken together, the findings of this study demonstrate that SD induces reproductive dysfunction via glutathione-dependent defense depletion and down-regulation of NO/cGMP signaling, which was abolished by glutamine supplementation.


Assuntos
GMP Cíclico/metabolismo , Glutamina/farmacologia , Óxido Nítrico/metabolismo , Disfunções Sexuais Fisiológicas/patologia , Privação do Sono/patologia , Testículo/patologia , Animais , Antioxidantes/farmacologia , Epididimo/efeitos dos fármacos , Epididimo/metabolismo , Disfunção Erétil/patologia , Libido/efeitos dos fármacos , Libido/fisiologia , Masculino , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/fisiologia , Distribuição Aleatória , Ratos , Ratos Wistar , Testículo/efeitos dos fármacos
6.
J Womens Health (Larchmt) ; 31(3): 391-400, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-35230162

RESUMO

Background: Hypoactive sexual desire disorder (HSDD), the most prevalent female sexual dysfunction, is characterized as persistent diminished desire for sexual activity accompanied by distress. The efficacy and safety of bremelanotide, a melanocortin receptor agonist approved by the U.S. Food and Drug Administration for treatment of acquired generalized HSDD in premenopausal women, were established in the phase 3 RECONNECT studies, two identically designed double-blind randomized placebo-controlled studies with an optional 52-week open-label extension. This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) in the RECONNECT studies. Materials and Methods: Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 for bremelanotide versus placebo. Results: Among 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone quartiles, with few exceptions. Bremelanotide was further associated with statistically significant increases in reported sexual desire (p < 0.05) in patients not taking hormonal contraceptives, and with a numerical advantage in those taking hormonal contraceptives. Patients treated with bremelanotide experienced decreased distress compared with those in the placebo group at levels of statistical significance (p < 0.05) regardless of hormonal contraceptive use. Statistically significant improvements were observed in the presence or absence of decreased arousal, and regardless of HSDD duration. Conclusions: Bremelanotide was associated with statistically significant improvements in sexual desire and reduced distress across several prespecified subgroups, with few exceptions.


Assuntos
Disfunções Sexuais Psicogênicas , alfa-MSH , Feminino , Humanos , Libido , Peptídeos Cíclicos/efeitos adversos , Disfunções Sexuais Psicogênicas/tratamento farmacológico , alfa-MSH/efeitos adversos , alfa-MSH/uso terapêutico
8.
J Sex Med ; 19(4): 553-568, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35227621

RESUMO

BACKGROUND: The benefits of treatment with testosterone (T) in women with loss of desire suggest that low androgens may distinguish women with sexual dysfunction (SD) from others; however, evidence on this point is lacking. AIM: To answer the question: is there an association between endogenous levels of androgens and sexual function in women? METHODS: An extensive search was performed in MEDLINE, Embase and PsycInfo. Four separate meta-analyses were conducted for total T, free T, Free Androgen Index (FAI), and Dehydroepiandrosterone sulphate (DHEAS). Cohort, cross-sectional, and prospective studies were included. OUTCOMES: The main outcome was the association between endogenous androgens and sexual desire. Global sexual function was considered as a secondary outcome. The effect measure was expressed as standardized mean difference (SMD). RESULTS: The meta-analysis on total T included 34 studies involving 3,268 women, mean age 36.5 years. In 11 studies, a significant association was found between sexual desire, measured by validated psychometric instruments, and total T (SMD = 0.59 [0.29;0.88], P < 0.0001), with a moderate effect. The association with global sexual function (n = 12 studies) was also significant (SMD = 0.44 [0.21;0.67], P <0.0001). Overall, total T was associated with a better sexual function (SMD = 0.55 [0.28;0.82)], P < 0.0001), with similar results obtained when poor quality studies were removed. Age showed a negative relationship with the overall outcome. No differences were found when stratifying the studies according to menopausal status, type of menopause, age at menopause, use of hormonal replacement therapy, relationship status, method for T measurement, phase of the menstrual cycle or use of hormonal contraception. The meta-analysis of T derivatives (free T and FAI) also showed a significant, moderate association with sexual desire. In contrast, DHEAS seems not to exert any significant influence on desire, whilst showing a positive association with global sexual function. CLINICAL IMPLICATIONS: Endogenous androgens show a moderate association with a better sexual function in women; however, the role of psychological, relational and other hormonal factors should not be overlooked. STRENGTHS & LIMITATIONS: This represents the first attempt at meta-analyzing data available on the topic. A significant publication bias was found for total T. CONCLUSION: There appears to be a moderate association between total T and sexual desire/global sexual function, which is confirmed, although weak, in studies employing liquid chromatography-mass spectrometry (LC-MS). Similar results on desire were obtained for free T and FAI. DHEAS only showed a positive association with global sexual function. More research is needed. Maseroli E and Vignozzi L. Are Endogenous Androgens Linked to Female Sexual Function? A Systemic Review and Meta-Analysis. J Sex Med 2022;19:553-568.


Assuntos
Androgênios , Disfunções Sexuais Psicogênicas , Adulto , Androgênios/uso terapêutico , Estudos Transversais , Feminino , Humanos , Libido , Estudos Prospectivos , Disfunções Sexuais Psicogênicas/tratamento farmacológico , Testosterona/uso terapêutico
9.
Aging Male ; 25(1): 65-71, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35243960

RESUMO

OBJECTIVE: To investigate whether routine assessment of free testosterone improves the diagnostic accuracy of functional hypogonadism. METHODS: Total and free testosterone (calculated on SHBG levels) were determined in 188 patients with sexual symptoms and 184 with infertility. RESULTS: Hypogonadism (calculated free testosterone <63 pg/ml) was found in 47/188 (25.0%) patients with sexual symptoms and in 21/184 (11.4%) with infertility. Total testosterone determination misdiagnosed hypogonadism in 8.4% (12/143) of men with sexual symptoms and in 2% (3/152) with infertility. In subjects with borderline total testosterone, only 24.7% (19/77) had hypogonadism confirmed by free testosterone levels. Free testosterone levels significantly correlated with age, haematocrit, gonadotropins, gynecomastia, BMI, and number of co-morbidities, whereas total testosterone associated only with the latter two. Furthermore, age, haematocrit, BMI, and the presence of erectile dysfunction and of low libido were significantly different between men with normal and low free testosterone, whereas only BMI and low libido were significantly different between patients with normal and low total testosterone. CONCLUSION: Routine assessment of free testosterone allows a more accurate diagnosis of functional hypogonadism, especially in men with sexual symptoms. Free testosterone levels associate with clinical and biochemical parameters of androgen deficiency better than total testosterone levels.


Assuntos
Disfunção Erétil , Eunuquismo , Hipogonadismo , Disfunção Erétil/complicações , Eunuquismo/complicações , Humanos , Hipogonadismo/complicações , Libido , Masculino , Testosterona
10.
J Sex Med ; 19(5): 745-760, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35296386

RESUMO

BACKGROUND: Inflammation has been linked to a variety of mental and physical health outcomes that disproportionately impact women, and which can impair sexual function; thus, there is reason to expect a link between inflammation and women's sexual functioning. AIM: To test the hypothesis that higher concentrations of C-reactive protein (CRP), a general biomarker of inflammation, would predict women's lower sexual desire. METHOD: As 2 independent research teams, we conducted 3 separate studies (total n = 405) that assessed salivary CRP and various measurements of sexual desire in different women populations. OUTCOMES: Female Sexual Function Index, Sexual Desire Inventory-2, Decreased Sexual Desire Screener, and Sexual Interest and Desire Inventory. RESULTS: Regardless of the way sexual desire was measured (e.g., state vs trait; general desire vs. desire functioning) and the population sampled (i.e., healthy vs. clinically diagnosed with sexual dysfunction), all the studies revealed null results. CLINICAL IMPLICATIONS: While exploratory, the convergence of these null results across studies and researchers suggests that if there is an association between inflammation and women's sexual desire, it is likely very subtle. STRENGTHS & LIMITATIONS: Across 2 independent research teams, 3 unrelated studies, and various measurements of sexual desire, results were consistent. These points lend to the generalizability of the results. However, study designs were cross-sectional. CONCLUSIONS: Future research may reveal (i) a non-linear threshold effect, such that inflammation does not begin to impact women's sexual desire until it is at a high level, (ii) inflammatory biomarkers other than CRP might be more sensitive in detecting associations between inflammation and desire, should they exist, or (iii) the mechanisms underlying sexual dysfunction may differ between sexes. Clephane K, et al. Lack of Evidence for a Relationship Between Salivary CRP and Women's Sexual Desire: An Investigation Across Clinical and Healthy Samples. J Sex Med 2022;19:745-760.


Assuntos
Disfunções Sexuais Fisiológicas , Disfunções Sexuais Psicogênicas , Proteína C-Reativa , Feminino , Humanos , Inflamação , Libido , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Psicogênicas/diagnóstico , Disfunções Sexuais Psicogênicas/etiologia , Inquéritos e Questionários
11.
J Sex Med ; 19(5): 872-878, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35304850

RESUMO

BACKGROUND: Declining sexual desire over the course of a relationship may cause distress. Because sexual desire partly depends on who the (imagined) sexual partner is, this study focuses on increasing sexual desire for the long-term partner specifically. AIM: This study examined 3 regulation strategies: (i) positive reappraisal of the partner, (ii) reappraisal of sexual desire decline, and (iii) sexual imagery about the partner. We tested whether these 3 strategies increased (i) sexual desire for the partner, (ii) motivated attention for the partner, as indicated by the late positive potential (LPP) amplitude, and (iii) infatuation, attachment, and relationship satisfaction. METHODS: Twenty-five young adults (6 men) who were in a long-term relationship performed the regulation strategies and no regulation before passively viewing a picture of their partner. OUTCOMES: The LPP amplitude was measured during the partner picture. After each strategy, participants rated their sexual desire, infatuation, attachment, and relationship satisfaction. RESULTS: Participants felt more sexual desire for and more infatuated with their partner after sexual imagery about the partner than after no regulation. Participants also felt more attached to their partner after positive reappraisal of the partner than after no regulation. There was no evidence that any of the strategies influenced relationship satisfaction or motivated attention. CLINICAL IMPLICATIONS: Sexual imagery about the partner is a simple strategy that people can use without involving the partner to increase sexual desire for (and infatuation with) their long-term partner. STRENGTHS & LIMITATIONS: One of the strengths of the current study is the experimental manipulation of strategy use within participants, which allows for conclusions of causality. The main limitation is the small, inclusive convenience sample. This study had good power to detect medium effects but was underpowered to detect small effects. Participants were mostly young adult women in relatively short long-term relationships. Gender differences in the effectiveness of the 3 strategies were not hypothesized or tested. CONCLUSION: Sexual imagery about the partner increases sexual desire for (and infatuation with) the partner. Langeslag SJE, Davis LL. A Preliminary Study on Up-regulation of Sexual Desire for a Long-term Partner. J Sex Med 2022;19:872-878.


Assuntos
Libido , Parceiros Sexuais , Feminino , Humanos , Libido/fisiologia , Masculino , Satisfação Pessoal , Comportamento Sexual , Regulação para Cima , Adulto Jovem
12.
Arch Sex Behav ; 51(3): 1559-1575, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35182284

RESUMO

Beliefs about sexuality tend to become more salient during sexual challenges and are associated with how individuals respond to these difficulties and, in turn, their sexual well-being. The transition to parenthood is marked by significant changes to couples' sexuality. As such, this period of vulnerability may be an important context in which these beliefs impact how couples manage sexual stressors and may have implications for their sexual well-being. In a longitudinal dyadic study, we examined whether couples' sexual growth beliefs (e.g., beliefs that sexual problems can be resolved through effort) and sexual destiny beliefs (e.g., beliefs that sexual problems reflect incompatibility with their partner) correspond with changes to various facets of couples' sexual well-being over time. First-time parent couples (N = 203) completed online surveys assessing these beliefs in pregnancy (32 weeks) and measures of sexual well-being (satisfaction, desire, and distress) in pregnancy (20 and 32 weeks) and across the postpartum period (3, 6, 9, 12 months). Dyadic latent growth curve models showed that expectant mothers who reported stronger sexual destiny beliefs in pregnancy reported higher sexual distress and lower sexual satisfaction at 3 months postpartum. When partners reported stronger sexual destiny beliefs in pregnancy, both they and new mothers reported greater sexual desire at 3 months postpartum. Unexpectedly, partners' higher sexual growth beliefs in pregnancy predicted mothers' lower sexual desire at 3 months postpartum. Sexual growth and destiny beliefs were not associated with change in couples' sexual well-being beyond 3 months postpartum. Findings shed light on the potential benefits and costs of sexual growth and destiny beliefs for couples' sexual well-being early in the postpartum period, but not over time.


Assuntos
Comportamento Sexual , Parceiros Sexuais , Feminino , Humanos , Libido , Orgasmo , Período Pós-Parto , Gravidez
13.
J Womens Health (Larchmt) ; 31(2): 171-182, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35147466

RESUMO

Background: Bremelanotide, a melanocortin receptor agonist, is Food and Drug Administration (FDA)-approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). Results: The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 months. The most common adverse events (AEs) were nausea (40.0% vs. 1.3%), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4 vs. 0.5), bremelanotide versus placebo groups, respectively, in the integrated double-blind portion of the phase 3 studies (N = 1247). Nausea was the most common reason for bremelanotide discontinuation. There were no deaths; a few subjects experienced serious AEs. Focal hyperpigmentation was rare when bremelanotide was dosed in accordance with label recommendations, but it occurred in more than one-third of subjects following up to 16 consecutive daily dosings. Small and transient but statistically significant blood pressure increases were observed during ambulatory blood pressure monitoring. Most drug-drug interactions were not clinically significant, except for interactions that lowered plasma concentrations of indomethacin and naltrexone. In the double-blind portion of the integrated phase 3 studies, 70% of the bremelanotide group proceeded to the open-label phase of the studies versus 87% of those on placebo. Conclusions: The AEs associated with bremelanotide are mostly mild to moderate. Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Clinical Trial Registration number: NCT02333071 [Study 301] and NCT02338960 [Study 302].


Assuntos
Monitorização Ambulatorial da Pressão Arterial , Libido , Método Duplo-Cego , Feminino , Humanos , Peptídeos Cíclicos/efeitos adversos , alfa-MSH/efeitos adversos
14.
Curr Psychiatry Rep ; 24(2): 99-109, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35102537

RESUMO

PURPOSE OF REVIEW: This review article discusses the controversy in the DSM-5 conceptualization and diagnostic criteria for female sexual dysfunction (FSD). An overview of recent studies on available treatments for hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD) is provided. RECENT FINDINGS: Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions. There are a wide range of pharmacological, other physiological, and psychological treatment options available for women with FSD, which can be offered based on their specific symptoms, potential benefits/risks, and preferences.


Assuntos
Disfunções Sexuais Fisiológicas , Disfunções Sexuais Psicogênicas , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Libido , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Disfunções Sexuais Psicogênicas/tratamento farmacológico , Testosterona/uso terapêutico
15.
Arch Sex Behav ; 51(1): 417-440, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-35031906

RESUMO

In most theoretical models, sexual desire for one's partner is predominantly conceptualized from an individual perspective. There is, however, a growing body of empirical evidence on the dyadic aspects of sexual desire. That evidence is as yet not well-integrated into theoretical conceptualizations of sexual desire. Aiming to fill this gap, we present the Dyadic Interactions Affecting DyadIC Sexual desire model (DIADICS), a new conceptual model inspired by systems theory that describes how dyadic interactions between partners influence dyadic sexual desire in romantic relationships. After defining dyadic sexual desire, we discuss (1) the structure of dyadic interactions, (2) their content, and (3) the process through which they affect dyadic sexual desire in a romantic relationship. Thereafter, we review theoretical, clinical, and empirical insights underscoring the relation between dyadic interactions and (dyadic) sexual desire, use DIADICS as a framework for understanding fluctuations in dyadic sexual desire in long-term relationships, and conclude by discussing implications of DIADICS for research and clinical practice.


Assuntos
Comportamento Sexual , Parceiros Sexuais , Humanos , Relações Interpessoais , Libido
17.
Arch Sex Behav ; 51(1): 547-564, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34997399

RESUMO

Although some evidence exists to suggest that single (i.e., unpartnered) individuals are less sexually satisfied on average than are partnered individuals, it is unclear whether the variables correlating with each group's sexual satisfaction are similar or different. This research sought to examine how desire for and actual engagement in solitary and partnered sexual activities are associated with both groups' sexual satisfaction. We first conducted a preliminary study (n = 572) to test and refine existing measures of sexual satisfaction for applicability across relationship status. In two follow-up studies (N = 1,238), measurement invariance (across relationship status and gender) of the resulting 4-item sexual satisfaction scale was established. Further, results across the studies showed that for singles dyadic sexual desire was negatively related to sexual satisfaction, whereas no significant link was found with solitary desire. For individuals in romantic relationships, having higher sexual desire involving a partner and lower solitary desire were both associated with greater sexual satisfaction. When analyzing participants' responses on the desired and actual frequency of engaging in specific sexual acts, we found that for both single and partnered individuals, frequent engagement in partnered acts was associated with greater sexual satisfaction. Wanting frequent engagement in partnered acts was associated with lower sexual satisfaction for both groups, but only if the current frequency of engaging in these acts was low. These findings suggest that at least during the COVID-19 pandemic, meeting desires for partnered sex plays an important role in maintaining a sexually satisfying life, regardless of one's relationship status.


Assuntos
COVID-19 , Orgasmo , Humanos , Libido/fisiologia , Orgasmo/fisiologia , Pandemias , Satisfação Pessoal , SARS-CoV-2 , Comportamento Sexual , Parceiros Sexuais
18.
Int J Impot Res ; 34(1): 93-99, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33199846

RESUMO

Orgasm and sexual desire are components of the human sexual response. The main objective of this study was to examine the relationship between the sexual desire and dimensions of the subjective orgasm experience. A sample composed of 1161 heterosexual adults, distributed into three age groups (18-34, 35-49, and 50 years old or older), completed a background questionnaire, the Orgasm Rating Scale, and the Sexual Desire Inventory. First, the effect that sex and age have on the subjective orgasm experience was analyzed. Second, correlations between sexual desire and orgasm experience were examined. Also, the predictive capacity that dimensions of sexual desire have on the subjective orgasm experience in the context of sexual relationship was examined. Results showed that age had a significant effect on the intensity of the subjective orgasm experience perceived during sexual relationships with a partner and that this experience decreased as people get older. There was an association between the components of sexual desire and the dimensions of subjective orgasm experience. Furthermore, partner-focused sexual desire contributed in a relevant manner to the subjective orgasm experience. Implications for both research and clinical field are also discussed.


Assuntos
Libido , Orgasmo , Adolescente , Adulto , Heterossexualidade , Humanos , Libido/fisiologia , Orgasmo/fisiologia , Comportamento Sexual/fisiologia , Inquéritos e Questionários
19.
J Sex Marital Ther ; 48(4): 323-342, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34693896

RESUMO

Throughout the previous decade, research exploring the associations between mindfulness and sexual dysfunction has grown exponentially. Researchers have highlighted inverse associations between mindfulness and various sexual dysfunctions, including erectile dysfunction, hypersexuality, and sexual distress, as well as positive associations between mindfulness and sexual desire, sexual satisfaction, and overall sexual functioning. This study sought to describe the state of extant literature exploring the association between mindfulness and sexual dysfunction, identify areas for future study within this area of research, and inform clinical practice when working with those experiencing sexual dysfunction. A systematic search of peer-reviewed journal articles revealed a final sample of 18 articles. After collecting data from all included articles, results support the inverse association between mindfulness and various sexual dysfunctions. Additionally, results highlight that current mindfulness and sexual dysfunction literature focuses more on the individual's experience and does not fully consider how the couple system is often impacted by, and may contribute to, the maintenance of sexual dysfunction. Furthermore, results demonstrate the importance of including LGBTQ + populations in future research, as extant literature in this area has focused primarily on the heterosexual experience.


Assuntos
Atenção Plena , Disfunções Sexuais Fisiológicas , Disfunções Sexuais Psicogênicas , Humanos , Libido , Masculino , Atenção Plena/métodos , Orgasmo
20.
Arch Sex Behav ; 51(1): 565-576, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34697691

RESUMO

Virtual reality (VR) media using a three-dimensional (3D) camera facilitates an immersive experience compared to traditional two-dimensional (2D) formats. In this novel study, we used high quality, women-centered erotica and examined whether stimulus modality (VR vs. 2D) and point of view (POV: first-person vs. third-person) impacted women's feelings of sexual presence (activation of sexual response induced by the perception of being present), sexual arousal, and sexual desire (dyadic and solitary). We also investigated the effects of stimulus modality on feelings of general presence (a sense of "being there"). Results from 38 women indicated that with medium to large effects, general presence, sexual presence, and sexual arousal were significantly higher for VR videos relative to 2D videos. Sexual presence was higher for first-person POV depending on the order of film exposure. A general trend toward increasing dyadic sexual desire over the course of the study was observed. No significant differences were observed for solitary sexual desire. These findings support the adaptability of VR media to sex research and show that it can induce feelings of sexual presence and presence more generally. That sexual arousal was positively impacted by VR erotica may have implications for addressing the limitations that accompany other stimulus modalities used to elicit sexual responses in women.


Assuntos
Literatura Erótica , Realidade Virtual , Nível de Alerta/fisiologia , Feminino , Humanos , Libido/fisiologia , Excitação Sexual , Comportamento Sexual/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...